Arbutus Biopharma Corp (ABUS)
ABUS Stock Price Chart
Explore Arbutus Biopharma Corp interactive price chart. Choose custom timeframes to analyze ABUS price movements and trends.
ABUS Company Profile
Discover essential business fundamentals and corporate details for Arbutus Biopharma Corp (ABUS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
26 Jul 2007
Employees
19.00
Website
http://www.arbutusbio.comCEO
Lindsay Androski
Description
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
ABUS Financial Timeline
Browse a chronological timeline of Arbutus Biopharma Corp corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is -$0.02, while revenue estimate is $700.00k.
Earnings released on 13 May 2026
EPS came in at $0.87 surpassing the estimated -$0.03 by +3.00k%, while revenue for the quarter reached $179.13m , beating expectations by +23.78k%.
Earnings released on 23 Mar 2026
EPS came in at -$0.01 surpassing the estimated -$0.04 by +71.47%, while revenue for the quarter reached $1.05m , beating expectations by +71.03%.
Earnings released on 13 Nov 2025
EPS came in at -$0.04 surpassing the estimated -$0.06 by +28.57%, while revenue for the quarter reached $529.00k , missing expectations by -37.10%.
Earnings released on 6 Aug 2025
EPS came in at $0.01 surpassing the estimated -$0.02 by +150.00%, while revenue for the quarter reached $10.74m , beating expectations by +574.98%.
Earnings released on 14 May 2025
EPS came in at -$0.13 falling short of the estimated -$0.09 by -44.44%, while revenue for the quarter reached $1.76m , missing expectations by -21.32%.
Earnings released on 27 Mar 2025
EPS came in at -$0.07 surpassing the estimated -$0.08 by +12.50%, while revenue for the quarter reached $1.57m , missing expectations by -30.26%.
Earnings released on 6 Nov 2024
EPS came in at -$0.10 matching the estimated -$0.10, while revenue for the quarter reached $1.34m , missing expectations by -15.25%.
Earnings released on 1 Aug 2024
EPS came in at -$0.11 falling short of the estimated -$0.10 by -10.00%, while revenue for the quarter reached $1.73m , missing expectations by -6.70%.
Earnings released on 2 May 2024
EPS came in at -$0.10 matching the estimated -$0.10, while revenue for the quarter reached $1.53m , missing expectations by -28.74%.
Earnings released on 29 Feb 2024
EPS came in at -$0.12 matching the estimated -$0.12, while revenue for the quarter reached $2.15m , missing expectations by -55.22%.
Earnings released on 7 Nov 2023
EPS came in at -$0.12 matching the estimated -$0.12, while revenue for the quarter reached $4.66m , missing expectations by -2.76%.
Earnings released on 3 Aug 2023
EPS came in at -$0.10 surpassing the estimated -$0.12 by +16.67%, while revenue for the quarter reached $4.65m , missing expectations by -24.50%.
Earnings released on 4 May 2023
EPS came in at -$0.10 surpassing the estimated -$0.14 by +28.57%, while revenue for the quarter reached $6.69m , beating expectations by +10.90%.
Earnings released on 2 Mar 2023
EPS came in at -$0.14 matching the estimated -$0.14, while revenue for the quarter reached $6.25m , beating expectations by +1.13%.
Earnings released on 9 Nov 2022
EPS came in at -$0.12 matching the estimated -$0.12, while revenue for the quarter reached $5.95m , missing expectations by -36.51%.
Earnings released on 4 Aug 2022
EPS came in at -$0.10 surpassing the estimated -$0.13 by +23.08%, while revenue for the quarter reached $14.24m , beating expectations by +110.43%.
Earnings released on 5 May 2022
EPS came in at -$0.11 surpassing the estimated -$0.13 by +15.38%, while revenue for the quarter reached $12.58m , beating expectations by +188.03%.
Earnings released on 3 Mar 2022
EPS came in at -$0.15 surpassing the estimated -$0.16 by +6.25%, while revenue for the quarter reached $3.21m , beating expectations by +11.21%.
Earnings released on 4 Nov 2021
EPS came in at -$0.24 matching the estimated -$0.24, while revenue for the quarter reached $3.34m , beating expectations by +40.34%.
Earnings released on 5 Aug 2021
EPS came in at -$0.23 falling short of the estimated -$0.21 by -9.52%, while revenue for the quarter reached $2.33m , beating expectations by +9.86%.
ABUS Stock Performance
Access detailed ABUS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
